Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-21-005194
Filing Date
2021-03-02
Accepted
2021-03-02 15:24:22
Documents
71
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 876005
2 ex4-4.htm EX-4.4 35525
3 ex31-1.htm EX-31.1 11896
4 ex31-2.htm EX-31.2 11920
5 ex32.htm EX-32 6769
  Complete submission text file 0001493152-21-005194.txt   4546763

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE FILE pvct-20201231.xml EX-101.INS 771949
7 XBRL SCHEMA FILE pvct-20201231.xsd EX-101.SCH 58426
8 XBRL CALCULATION FILE pvct-20201231_cal.xml EX-101.CAL 63254
9 XBRL DEFINITION FILE pvct-20201231_def.xml EX-101.DEF 196711
10 XBRL LABEL FILE pvct-20201231_lab.xml EX-101.LAB 392686
11 XBRL PRESENTATION FILE pvct-20201231_pre.xml EX-101.PRE 299418
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36457 | Film No.: 21703122
SIC: 2834 Pharmaceutical Preparations